An update on ripasudil for the treatment of glaucoma and ocular hypertension

被引：16
|
作者：
Testa, V [1 ,2 ]
Desideri, L. Ferro [1 ,2 ]
Della Giustina, P. [1 ,2 ]
Traverso, C. E. [1 ,2 ]
Iester, M. [1 ,2 ]
机构：
[1] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy
[2] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy
来源：
DRUGS OF TODAY | 2020年 / 56卷 / 09期
关键词：
Ripasudil; Rho-associated protein kinase (ROCK) inhibitors; Glaucoma; Ocular hypertension; Ophthalmic drugs; RHO-KINASE INHIBITOR; OPEN-ANGLE GLAUCOMA; FUCHS ENDOTHELIAL DYSTROPHY; EYE DROP RIPASUDIL; INTRAOCULAR-PRESSURE; ROCK INHIBITOR; TRABECULAR MESHWORK; K-115; H-7; CONTRACTION;
D O I：
10.1358/dot.2020.56.9.3178110
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Ripasudil (K-115) is a novel Rho-associated protein kinase (ROCK) inhibitor. The Rho-ROCK pathway regulates key downstream effectors involved in many cellular functions, in particular in the actin cytoskeleton activity. The clinical effects of ripasudil expected on the eye include an intraocular pressure-lowering effect and a wound-healing activity on corneal endothelial cells, but many other functions are currently under investigation. To date, ripasudil has been approved in Japan (2014) for the treatment of glaucoma and ocular hypertension, and several clinical trials are currently investigating its role in the treatment of Fuchs' corneal dystrophy. In this review, we will discuss its pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.
引用
收藏
页码：599 / 608
页数：10
相关论文
共 50 条
  • [1] Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma
    Inoue, Toshihiro
    Tanihara, Hidenobu
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1669 - 1673
  • [2] Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection
    Kusuhara, Sentaro
    Nakamura, Makoto
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 1229 - 1236
  • [3] Late-Onset Ocular Hypotensive Effect of Ripasudil on Primary Open-Angle Glaucoma
    Sano, Kei
    Terauchi, Ryo
    Fukai, Kota
    Ogawa, Shumpei
    Noro, Takahiko
    Tatemichi, Masayuki
    Nakano, Tadashi
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 3905 - 3912
  • [4] Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
    Tanihara, Hidenobu
    Kakuda, Takahiko
    Sano, Tetsuro
    Kanno, Takashi
    Kurihara, Yuji
    ADVANCES IN THERAPY, 2022, 39 (04) : 1659 - 1677
  • [5] Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension
    Desideri, L. Ferro
    Cutolo, C. A.
    Barra, F.
    Ferrero, S.
    Traverso, C. E.
    DRUGS OF TODAY, 2019, 55 (06) : 377 - 384
  • [6] Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
    Tanihara, Hidenobu
    Kakuda, Takahiko
    Sano, Tetsuro
    Kanno, Takashi
    Imada, Ryosuke
    Shingaki, Wataru
    Gunji, Ryoji
    ADVANCES IN THERAPY, 2019, 36 (02) : 333 - 343
  • [7] Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma
    Mohapatra, Sumita
    Thakur, Subhodeep
    Panda, Bijnya B.
    Das, Priti
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (07) : 2756 - 2759
  • [8] Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
    Tanna, Angelo P.
    Johnson, Mark
    OPHTHALMOLOGY, 2018, 125 (11) : 1741 - 1756
  • [9] Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
    Tanihara, Hidenobu
    Inoue, Toshihiro
    Yamamoto, Tetsuya
    Kuwayama, Yasuaki
    Abe, Haruki
    Suganami, Hideki
    Araie, Makoto
    ACTA OPHTHALMOLOGICA, 2015, 93 (04) : E254 - E260
  • [10] One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension
    Tanihara, Hidenobu
    Inoue, Toshihiro
    Yamamoto, Tetsuya
    Kuwayama, Yasuaki
    Abe, Haruki
    Fukushima, Atsuki
    Suganami, Hideki
    Araie, Makoto
    ACTA OPHTHALMOLOGICA, 2016, 94 (01) : E26 - E34
12345